Vizsgálati helyszín
Pro Life Medica Sp. z o.o.
Lublin, 20-412, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 8futó vizsgálat
- 12lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis4 vizsgálat
- 4. fázis3 vizsgálat
- Állapot
- Lezárult12 vizsgálat
- Fut, nem toboroz6 vizsgálat
- Toboroz2 vizsgálat
- Fő szponzor
- Argenx2 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- AstraZeneca1 vizsgálat
- Bristol-Myers Squibb1 vizsgálat
- Celldex Therapeutics1 vizsgálat
- és még 13
Futó vizsgálatok
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830· 2. fázis· Neuron23 Inc.· Forrás
Fut, nem toboroz
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· 3. fázis· Celldex Therapeutics· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351· 3. fázis· Ionis Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· 4. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03604198· 2. fázis· Corcept Therapeutics· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicentre clinical trial
2023-505875-56-00· 4. fázis· KRKA tovarna zdravil d.d. Novo mesto· Forrás
Lezárult
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)
NCT06684847· 3. fázis· Argenx· Forrás
Lezárult
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
2024-510826-16-00· 3. fázis· Mabxience Research S.L.· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
NCT06920771· 3. fázis· HAL Allergy· Forrás
Lezárult
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· 3. fázis· Incyte Corporation· Forrás
Lezárult
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS)
2023-503915-14-00· 2. fázis· Argenx· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· 3. fázis· Takeda· Forrás
Lezárult
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT05742802· 3. fázis· AstraZeneca· Forrás
Lezárult
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Lezárult
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
NCT04306315· 4. fázis· LEO Pharma· Forrás
Lezárult
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
NCT04921384· 3. fázis· H. Lundbeck A/S· Forrás
Hibát jelzek